Communication is very important for people to be successfully integrated into social environment and make and maintain relationship. Particularly, language difficulties lead to social exclusion of the people affected with Alzheimer's disease (AD) and contribute to a significant decrease in the quality of their life and also have a big impact on their family members who in most cases become their caregivers who need to communicate with their loved ones in order to meet their needs. Therefore, the goal of this study is to describe language impairments in the individual phases of AD and discuss their improvement with respect to AD on the basis of literature review. The authors of this article use traditional research methods in order to achieve the goal set mentioned earlier. First, a method of literature review of available sources describing language impairments in the individual phases of AD is exploited. Second, to show how informal caregivers and relevant drugs can successfully intervene in the improvement of these language impairments, a method of comparison of different research studies exploring such social intervention and medical treatment is used.

Center for Basic and Applied Research Faculty of Informatics and Management University of Hradec Kralove Hradec Kralove Czech Republic ; Biomedical Research Center University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Applied Linguistics University of Hradec Kralove Hradec Kralove Czech Republic

Department of Economics Faculty of Informatics and Management University of Hradec Kralove Hradec Kralove Czech Republic

Department of Neurology 2nd Faculty of Medicine Charles University Prague and Motol University Hospital Prague Czech Republic ; International Clinical Research Center St Anne's University Hospital Brno Brno Czech Republic

Department of Neurology Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove Charles University Prague Hradec Kralove Czech Republic

Zobrazit více v PubMed

OECD Database Data: Population Development, Historical Data and Forecast. 2015. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: http://stats.oecd.org/#.

WHO International Classification of Diseases (ICD) 1994. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: http://www.who.int/classifications/icd/en/

Stages of Alzheimer’s. Alzheimer’s Association 2015. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: http://www.alz.org/alzheimers_disease_stages_of_alzheimers.asp.

Klímová B, Marešová P, Kuča K. Assistive technologies for language disorders in dementia [in review] PubMed PMC

Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–292. PubMed PMC

Alzheimer’s Association Alzheimer’s Disease Facts and Figures. Alzheimer’s and Dementia. 2012. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: http://www.alz.org/downloads/Facts_Figures_2012.pdf.

Website of Charles F and Joanne Knight Alzheimer’s Disease Research Center (Knight ADRC) Washington University School of Medicine in St Louis; Missouri, USA: 2003. [Accessed April 20, 2015]. Dementia of the Alzheimer’s Type – Description of Stages. [cited June 9, 2015]. Available from: http://knightadrc.wustl.edu/About_Us/PDFs/Stages_of_AD.pdf.

National Institute on Aging . Alzheimer’s Disease. Unraveling 2 the Mystery; US: 2012. [Accessed April 20, 2015]. [cited Jun 9, 2015]. Available from: https://www.nia.nih.gov/sites/default/files/alzheimers_disease_unraveling_the_mystery.pdf.

Frederiks C, Hofmann MT, Reichard T. Advances in diagnosis and treatment of Alzheimer’s disease. Hosp Physician. 2002;5:47–54.

Macoir J, Laforce R, Jr, Monetta L, Wilson M. Language deficits in major forms of dementia and primary progressive aphasias: an update according to new diagnostic criteria. Geriatr Psychol Neuropsychiatr Vieil. 2014;12(2):199–208. PubMed

Shivanand P. Review on Alzheimer’s disease: its cause, symptoms, and treatment at worldwide. Int J Appl Biol Pharm Technol. 2009;1(1):112–120.

Eliopoulos C, Carson VB, Varcarolis E. Evolve Resources for Varcarolis’ Foundations of Psychiatric Mental Health Nursing. St Louis, MO: Saunders Elsevier; 2006. Cognitive disorders.

Pekkala S. Semantic Fluency in Mild and Moderate Alzheimer’s Disease. Helsinki: Hakapaino Oy; 2004.

Orange JB, Colton-Hudson A. Enhancing communication in dementia of the Alzheimer’s type. Top Geriatr Rehabil. 1998;14(2):56–75.

Savundranayagam ME, Ryan EB, Anas AP, Orange JB. Communication and dementia: staff perceptions of conversational strategies. Clin Gerontol. 2007;31(2):47–63.

Ferris SH, Farlow M. Language impairment in Alzheimer’s disease and benefits of acetylcholinesterase inhibitors. Clin Interv Aging. 2013;8:1007–1014. PubMed PMC

Maresova P, Klimova B, Kuca K. Alzheimer’s disease: cost cuts call for novel drugs development and national strategy. Ceska A Slovenska Farmacie. 2015;64:25–30. PubMed

EC . European Initiative on Alzheimer’s Disease and Other Dementias. Brussels: 2009. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: http://ec.europa.eu/health/ph_information/dissemination/documents/com2009_380_en.pdf.

Savundranayagam MY, Hummert ML, Montgomery RJ. Investigating the effects of communication problems on caregiver burden. J Gerontol B Psychol Sci Soc Sci. 2005;60(1):S48–S55. PubMed

Ripich DN. Functional communication with AD patients: a caregiver training program. Alzheimer Dis Assoc Disord. 1994;8(3):95–109. PubMed

Manenti R, Repetto C, Bentrovato S, Marcone A, Bates E, Cappa SF. The effects of ageing and Alzheimer’s disease on semantic and gender priming. Brain. 2004;127(10):2299–2306. PubMed

Tang-Wai DF, Graham NL. Assessment of language function in dementia. Geriatr Aging. 2008;11:103–110.

Amieva H, Jacqmin-Gadda H, Orgogozo JM, et al. The 9-year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain. 2005;128:1093–1101. PubMed

Laws KR, Duncan A, Gale TM. “Normal’ semantic–phonemic fluency discrepancy in Alzheimer’s disease? A meta-analytic study. Cortex. 2010;46:595–601. PubMed

Stern Y, Albert S, Tang MX, Tsai WY. Rate of memory decline in AD is related to education and occupation: cognitive reserve? Neurology. 1999;53:1942–1957. PubMed

Fritsch T, McClendon MJ, Smyth KA, Ogrocki PK. Effects of educational attainment and occupational status on cognitive and functional decline in persons with Alzheimer-type dementia. Int J Geriatr Psychiatry. 2002;1:347–363. PubMed

Capitani E, Laiacona M, Basso A. Phonetically cued word-fluency, gender differences and aging: a reappraisal. Cortex. 1998;34:779–783. PubMed

Arrighi HM, Neumann PJ, Lieberburg IM, Townsend RJ. Lethality of Alzheimer disease and its impact on nursing home placement. Alzheimer Dis Assoc Disord. 2010;24(1):90–95. PubMed

DementiaGuide 2015. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: http://www.dementiaguide.com/symptomlibrary/memorylanguage/language_difficulty/managementstrategies/

Zemek F, Drtinova L, Nepovimova E, et al. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf. 2014;13(6):759–774. PubMed

Nepovimova E, Uliassi E, Korabecny J, et al. Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects. J Med Chem. 2014;57(20):8576–8589. PubMed

Hilari K, Needle JJ, Harrison KL. What are the important factors in health-related quality of life for people with aphasia? A systematic review. Arch Phys Med Rehabil. 2012;93(suppl 1):86–95. PubMed

Ferris S, Ihl R, Robert P, et al. Treatment effects of memantine on language in moderate to severe Alzheimer’s disease patients. Alzheimers Dement. 2009;5:369–374. PubMed

Winblad B, Kilander L, Eriksson S, et al. Severe Alzheimer’s Disease Study Group Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367(9516):1057–1065. PubMed

Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69(5):459–469. PubMed

Cummings J, Jones R, Wilkinson D, et al. Effect of donepezil on cognition in severe Alzheimer’s disease: a pooled data analysis. J Alzheimers Dis. 2010;21(3):843–851. PubMed

Winblad B, Black SE, Homma A, et al. Donepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trials. Curr Med Res Opin. 2009;25(11):2577–2587. PubMed

Schwam E, Xu Y. Cognition and function in Alzheimer’s disease: identifying the transitions from moderate to severe disease. Dement Geriatr Cogn Disord. 2010;29(4):309–316. PubMed

Ferris SH, Schmitt FA, Saxton J, et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer’s disease. Alzheimers Res Ther. 2011;3(3):22. PubMed PMC

Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2010;25(4):347–352. PubMed PMC

Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J. Reviews: effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2010;25(8):627–633. PubMed PMC

Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2009;8(1):39. PubMed

Clare L, Woods R. Cognitive rehabilitation in dementia. Neuropsychol Rehabil. 2001;11:193–517.

Zientz J, Rackley A, Chapman SB, et al. Evidence-based practice recommendations for dementia: educating caregivers on Alzheimer’s disease and training communication strategies. J Med Speech Lang Pathol. 2007;15(1):liii–lxiv.

Drug Treatment for Alzheimer’s Disease. 2015. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=147.

Mayo Clinic Staff Alzheimer’s: Drugs Help Manage Symptoms. 2014. [Accessed April 20, 2015]. [cited June 9, 2015]. Available from: http://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/a%20lzheimers/art-20048103.

Pope SK, Shue VM, Beck C. Will a healthy lifestyle help prevent Alzheimer’s disease. Annu Rev Public Health. 2003;24:111–132. PubMed

Kivipelto M, Solomon A. Alzheimer’s disease – the ways of prevention. J Nutr Health Aging. 2007;12:89–94. PubMed

Radak Z, Hart N, Sarga L, et al. Exercise plays a preventive role against Alzheimer’s disease. J Alzheimers Dis. 2010;20:777–783. PubMed

Rovio S, Kåreholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol. 2005;4:705–711. PubMed

Joe Verghese MD, Richard B, Lipton MD. Leisure Activities and the risk of dementia in the elderly. N Engl J Med. 2003;348:2508–2516. PubMed

Craik FIM, Bialystock E, Freedman M. Delaying the onset of Alzheimer’s disease. Bilingualism as a form of cognitive reserve. Neurology. 2010;75(19):1726–1729. PubMed PMC

Bialystok E, Craik FIM, Luk G. Bilingualism: consequences for mind and brain. Trends Cogn Sci. 2012;16(4):240–250. PubMed PMC

Bialystok E, Craik FIM, Freedman M. Bilingualism as a protection against the onset of symptoms of dementia. Neuropsychologia. 2007;45:459–464. PubMed

Soares FC, de Oliveira TC, de Macedo LD, et al. CANTAB object recognition and language tests to detect aging cognitive decline: an exploratory comparative study. Clin Interv Aging. 2015;10:37–48. PubMed PMC

Vestal L, Smith-Olinde L, Hicks G, Hutton T, Hart J., Jr Efficacy of language assessment in Alzheimer’s disease: comparing in-person examination and telemedicine. Clin Interv Aging. 2006;1(4):467–471. PubMed PMC

Sköldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease – a simulation study. Curr Alzheimer Res. 2013;10:207–216. PubMed

Soukup O, Jun D, Zdarova-Karasova J, et al. A resurrection of 7-MEOTA: a comparison with tacrine. Curr Alzheimer Res. 2013;10(8):893–906. PubMed

Neuropharmacology of Cevimeline and Muscarinic Drugs-Focus on Cognition and Neurodegeneration

The Effect of Mediterranean Diet on Cognitive Functions in the Elderly Population

Activities of Daily Living and Associated Costs in the Most Widespread Neurodegenerative Diseases: A Systematic Review

Enhancing Cognitive Performance of Healthy Czech Seniors through Non-Native Language Learning-A Mixed-Methods Pilot Study

Impact of Learning a Foreign Language on the Enhancement of Cognitive Functions Among Healthy Older Population

E-learning as valuable caregivers' support for people with dementia - A systematic review

Effect Of An Extra-Virgin Olive Oil Intake On The Delay Of Cognitive Decline: Role Of Secoiridoid Oleuropein?

Selected rare paediatric communication neurological disorders

Nitrendipine and Dementia: Forgotten Positive Facts?

Exploring assistive technology as a potential beneficial intervention tool for people with Alzheimer's disease - a systematic review

Multidomain Lifestyle Intervention Strategies for the Delay of Cognitive Impairment in Healthy Aging

Nutritional Interventions as Beneficial Strategies to Delay Cognitive Decline in Healthy Older Individuals

PPI Long Term Use: Risk of Neurological Adverse Events?

Bilingualism as a strategy to delay the onset of Alzheimer's disease

Mobile Phone Apps in the Management and Assessment of Mild Cognitive Impairment and/or Mild-to-Moderate Dementia: An Opinion Article on Recent Findings

Computer-Based Training Programs for Older People with Mild Cognitive Impairment and/or Dementia

Computer-Based Cognitive Training in Aging

Use of the Internet as a prevention tool against cognitive decline in normal aging

Prediction of population with Alzheimer's disease in the European Union using a system dynamics model

Assistive technologies for managing language disorders in dementia